1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial

Kakko, Johan; Svanborg, K.; Kreek, Mary Jeanne; Heilig, Markus

doi:10.1016/s0140-6736(03)12600-1

Cited by 418 publications

(263 citation statements)

References 24 publications

Supporting

Mentioning

244

Contrasting

Unclassified

Order By: Relevance

“…The findings in this study of significant superiority of buprenorphine compared to placebo on all of our primary drug use outcome measures and retention are consistent with the results of other placebo-controlled studies of buprenorphine in the U.S., 18,20,23 Norway 22 and Sweden. 21 The findings of significant superiority of buprenorphine compared to naltrexone for retention and time to resuming heroin use are unique. The results for buprenorphine treated patients in this study regarding retention and maximum duration of opioid abstinence are similar to previous studies of buprenorphine, 19 and the results for naltrexone treated patients were comparable to the results of many studies, 24,33,34 suggesting that the findings regarding the greater efficacy of buprenorphine compared to naltrexone or placebo may generalize to other populations and settings.…”

Section: Discussionmentioning

confidence: 99%

“…The lack of direct comparisons may contribute to policy makers' assumption that there are no advantages to introducing opioid agonist maintenance treatment (and continued prohibition of this treatment) if naltrexone maintenance treatment is available. Additionally, there are relatively few placebo-controlled clinical trials of either buprenorphine 18,[20][21][22][23] or naltrexone maintenance. 8,[11][12][13]24 Consequently, this double-blind, double-dummy, placebo-controlled randomized clinical trial compared the efficacy for maintaining heroin abstinence, preventing relapse, and reducing HIV risk behaviors following detoxification of 24 weeks of drug counseling alone (combined with placebo) or combined with maintenance with naltrexone or buprenorphine.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial

Schottenfeld

Mazlan²

2008

The Lancet

View full text Add to dashboard Cite

Background-Expanding access to effective treatments for heroin dependence is a global health priority that will also reduce HIV transmission. This study compares the efficacy for maintaining heroin abstinence, preventing relapse, and reducing HIV risk behaviors of three common treatments: detoxification followed by drug counseling only or drug counseling combined with opioid antagonist (naltrexone) or agonist (buprenorphine) maintenance treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial

Schottenfeld

Mazlan²

2008

The Lancet

View full text Add to dashboard Cite

show abstract

“…There is a very high rate of premature death among patients after discontinuities of opiates. [8][9][10] vii. Long-acting endorphin agonist (methadone, buprenorphine intramuscular heroin) has been standard treatment for addiction to opiates.…”

Section: Complex Evidence Of Antidepressant and Mood Altering Propertmentioning

confidence: 99%

Opiates: Benefits and Overuse Potential

Salerian¹

2015

PPIJ

View full text Add to dashboard Cite

This study reviews opiates (endorphin agonists) in treatment of pain and addiction with specific focus on their addictive potential versus benefits. This review suggests endorphin agonists enjoy mood stabilizing and antidepressant properties and have been helpful in treatment of pain, mood and addictive disorders. The evidence is consistent with the observation that slow release opiate preparations with long elimination life do have significant immunity against overuse. Collectively the evidence suggests longacting preparations of opiates are both effective to treat pain, addiction and some mood disorders and represent low risk for overuse.

show abstract

“…The buprenorphine mono-product, under the trade name Subutex, has been available for some time in other countries, notably in France since 1996 and in Australia since 2002. The bulk of clinical research supporting the approval of buprenorphine and the buprenorphinenaloxone combination has been conducted by US investigators, although other studies in Europe [36][37][38] and Australia [39] add to the weight of evidence for its clinical efficacy and safety. Some of the more crucial studies have been summarized in the Cochrane reviews [16].…”

Section: Clinical Studies Of Efficacy and Utilitymentioning

confidence: 99%

11 Buprenorphine for Opioid Dependence

Budd¹,

Raffa²

2005

Buprenorphine – The Unique Opioid Analgesic

View full text Add to dashboard Cite

As a treatment agent for opioid dependence, buprenorphine is a nearly ideal medication at our current stage of medication development. Unlike methadone, buprenorphine dosage can be rapidly adjusted with minimal potential for inducing severe consequences. In addition to its intrinsic safety, buprenorphine's relatively low abuse liability in the combination product (i.e., with naloxone as Suboxone ® ) makes it even more acceptable in regulatory quarters as well as to prescribing physicians. The approval of buprenorphine as a pharmacotherapy for opioid dependence returns to physicians the ability to treat their opioid-dependent patients with an effective opioid-based treatment for the first time in nearly 100 years. Buprenorphine is an opioid, however, and potential for misuse remains, even in combination with naloxone. Whether buprenorphine will be increasingly accepted as a treatment for opioid-dependent patients depends on clinicians recognizing the advantages of its uniquely useful properties while still heeding the need to manage their patients' therapy with reasonable vigilance. Keywordsbuprenorphine; heroin addiction; opioid dependence; pharmacotherapy; Suboxone ® Buprenorphine is a recent addition to the armamentarium for the treatment of opioid dependence, following legislation authorizing office-based prescribing in 2000 and subsequent approval in 2002 by the US FDA. As the buprenorphine-naloxone combination or in the monotherapy form, the medication boasts a unique pharmacological profile characterized by high levels of safety and a ceiling effect on respiratory suppression [1]. Thus, buprenorphine-based pharmacotherapy is well suited for use in clinical settings, with patients requiring less stringent oversight than is required for methadone maintenance [2][3][4]. Most importantly, buprenorphine is the first opioid-based medication in nearly a century to become available to clinicians in the USA for treatment of opioid dependence in the general practice setting. Buprenorphine offers physicians an acutely needed clinical tool, but

show abstract

1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial

Cited by 418 publications

References 24 publications

Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial

Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial

Opiates: Benefits and Overuse Potential

11 Buprenorphine for Opioid Dependence

Contact Info

Product

Resources

About